Patents by Inventor Rosette Lidereau

Rosette Lidereau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KINDLIN-1 AS A MARKER OF SENSITIVITY TO EGFR/RAS PATHWAY INHIBITORS
    Publication number: 20230184775
    Abstract: The present invention concerns an ex vivo method for selecting patient having cancer as eligible to EGFR/RAS pathway inhibitor therapy, an EGFR/RAS pathway inhibitor for use for treating cancer in a patient, and a method for prognosis cancer outcome or progression.
    Type: Application
    Filed: May 11, 2021
    Publication date: June 15, 2023
    Applicant: INSTITUT CURIE
    Inventors: Keltouma Driouch, Rosette Lidereau
  • PROGNOSIS FOR GLIOMA
    Publication number: 20150038357
    Abstract: Disclosed is a method of determining the survival prognosis of a patient afflicted by a glioma. The method includes assessing the level of expression of one or more specific gene in cells of the glioma.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 5, 2015
    Inventors: Dominique Joubert, Luc Bauchet, Jean-Philippe Hugnot, Ivan Bieche, Rosette Lidereau, Thierry Reme, Hugues Duffau, Valerie Rigau
  • NKX2.2 INHIBITORS AS DRUGS
    Publication number: 20140005249
    Abstract: The present invention relates to NKX2.2 inhibitors such as shRNAs for treating pathologies.
    Type: Application
    Filed: July 21, 2011
    Publication date: January 2, 2014
    Applicants: UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, INSTITUT CURIE
    Inventors: Jean-Philippe Hugnot, Pierre-Olivier Guichet, Marisa Teigell, Ivan Bieche, Rosette Lidereau, Dominique Joubert, Luc Bauchet, Valerie Rigau
  • METHOD FOR THE PROGNOSIS OF THE PROGRESSION OF CANCER
    Publication number: 20130224192
    Abstract: The present invention relates to methods for the prognosis of the progression of cancer in a patient, and more particularly methods for the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a cancer, in particular with a breast cancer, a lung cancer or other primary cancer, said methods comprising the step of detecting a higher expression level of FERMT1 gene in a tumour sample compared to a control reference values. The invention further relates to inhibitors of FERMT1 expression and their uses in the treatment of cancer or metastasis.
    Type: Application
    Filed: September 2, 2011
    Publication date: August 29, 2013
    Applicant: Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Rosette Lidereau, Keltouma Driouch, Soraya Sin, Florian Bonin
  • METHOD FOR PREDICTING THE OCCURRENCE OF METASTASIS IN BREAST CANCER PATIENTS
    Publication number: 20100113297
    Abstract: The present invention relates to the prognosis of the progression of breast cancer in a patient, and more particularly to the prediction of the occurrence of metastasis in one or more tissue or organ of patients affected with a breast cancer.
    Type: Application
    Filed: February 26, 2008
    Publication date: May 6, 2010
    Applicant: CENTRE RENE HUGUENIN
    Inventors: Rosette Lidereau, Keltouma Driouch, Thomas Landemaine
  • METHOD FOR DETECTING INTRAGENIC LARGE REARRANGEMENTS
    Publication number: 20090270270
    Abstract: The invention relates to methods for detecting at least one intragenic large rearrangement in a gene of interest, mapping the rearrangement breakpoint and diagnosing a genetic disease in a subject.
    Type: Application
    Filed: April 28, 2008
    Publication date: October 29, 2009
    Applicant: CENTRE RENE HUGUENIN
    Inventors: Etienne Rouleau, Cedrick Lefol, Sengul Tozlu-Kara, Rosette Lidereau
  • Pyrido (4,3-B) carbazoles substituted in the 1 position by a polyamine chain
    Patent number: 4434290
    Abstract: The novel derivatives correspond to the general formula: ##STR1## in which R.sub.1 is a Y--(CH.sub.2).sub.n --NR.sub.4 R.sub.5 group, where Y represents a single bond or the group ##STR2## R.sub.4 and R.sub.5, identical or different, are hydrogen or an alkyl radical, preferably a lower alkyl, or again form together a ring which can include heteroatoms, in particular nitrogen atoms. n is a number ranging from 1 to 10, notably from 2 to 7, R.sub.2 is a hydrogen atom, a lower alkyl group or an aralkyl group in which the alkyl substituent is a lower alkyl group, and R.sub.3 is a hydrogen atom or a CH.sub.3 group useful for the treatment of leukemias.
    Type: Grant
    Filed: May 1, 1981
    Date of Patent: February 28, 1984
    Assignee: Agence Nationale de Valorisation de la Recherche
    Inventors: Emile Bisagni, Claire Ducrocq, Christian Rivalle, Pierre Tambourin, Francoise Wendling, Alain Civier, Luc Montagnier, Jean-Claude Chermann, Jacqueline Gruest, Rosette Lidereau